Glioblastoma (GBM) is the most common primary brain tumor in adults, with a median survival of 14 months. Recently, research has centered on the role of the immune system in combating GBM’s progression. PD-1 is an immune checkpoint molecule on immune cells, which cancer cells take advantage of to shield themselves from the immune system. Anti-PD-1 therapy breaks down this shield, stimulating the immune cells to attack the tumor. Anti-PD-1 therapy has improved survival and benefited patients with different cancers, including GBM. Another new area of research is the role of glutamate, an abundant neurotransmitter in the brain, in glioma survival. It has been shown that glutamate receptors are expressed on glioma and stimulate cell death of tumor cells. My project investigated the survival effect of an anti-PD1 antibody combined with a glutamate receptor inhibitor, BVH-4157. We found that each treatment, independently and in combination, prolonged survival in mice. Additionally, we determined optimal dosing for using these two treatments in combination, resulting in prolonged survival over either therapy alone.